Current Vaccine Clinical Studies at the Vaccine Research Center

The Vaccine Research Center (VRC) is currently enrolling volunteers for a range of studies. If you are interested in volunteering to participate in a clinical trial, call 866-833-LIFE (5433), email

Studies Open to Accrual

VRC 200 (03-I-0263)
Apheresis Procedures to Obtain Plasma or Peripheral Blood Mononuclear Cells (PBMCs) for Research Studies

VRC 316 (17-I-0110 )
A Phase I Open-Label Clinical Trial To Evaluate Dose, Safety, Tolerability, And Immunogenicity Of An Influenza HA Ferritin Vaccine, Alone Or In Prime-Boost Regimens With An Influenza DNA Vaccine In Healthy Adults

VRC 317 (17-I-0058)
A Phase I Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

VRC 500 (11-I-0164)
Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes

VRC 603 (18-I-0030)
A Phase I Dose-Escalation Study of the Safety of AAV8-VRC07 (VRC-HIVAAV070-00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral -Treated, HIV-1 Infected Adults With Controlled Viremia

VRC 607 (16-I-0147 )
A Phase 1, Single Dose Study of the Safety and Virologic Effect of a Human MonoclonalAntibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults

VRC 608 (18-I-0069)
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

VRC 609 (18-I-0105)
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously to Healthy Adults

VRC 900 (10-I-0109)
Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

Content last reviewed on June 21, 2018